Biocorp strengthens its portfolio of connected insulin pens with Easylog
Biocorp Production, a French medical device supplier for large pharmaceutical companies, announced the launch of a new connected medical device, Easylog, intended to improve quality of life and treatment compliance for diabetic patients using insulin pens. Insulin pens are the most common insulin injection devices, already used by more than 50 million diabetic patients worldwide. According to Renhub Research, the 2014 insulin pen market was estimated at $10 billion, largely dominated by Novo Nordisk, Sanofi Pasteur, and Eli Lilly, holding more than 95% of the market.
Biocorp Production SA is a France-based company, which is specialised in the development and manufacturing of medical and drug delivery devices.
First French company dedicated to life sciences and healthcare company financing, Aurgalys assists private or listed companies during capital increase, provides equity research or valuation services, takes care of investor relations and assists the management for their strategy and business development. Listing Sponsor Alternext (NYSE Euronext). Conseil en Investissement Financier ORIAS - ACIFTE.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.